Instil Bio, Inc. Proceeds from Notes Payable
Instil Bio, Inc. (TIL) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-27
- Instil Bio, Inc. proceeds from notes payable for the quarter ending 2024-12-31 was $85.60M.
- Instil Bio, Inc. proceeds from notes payable for the quarter ending 2024-09-30 was $0.00.
- Instil Bio, Inc. proceeds from notes payable for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. proceeds from notes payable for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. proceeds from notes payable for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Instil Bio, Inc. proceeds from notes payable for fiscal 2024 was $85.60M.
- Instil Bio, Inc. proceeds from notes payable for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Instil Bio, Inc. proceeds from notes payable for fiscal 2022 was $70.34M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | ||||
| 2024-12-31 | $85.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $85.60M derived: sum of 2 quarters · filed 2026-03-27 | $85.60M derived: sum of 3 quarters · filed 2026-03-27 | $85.60M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | -$8.67M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | -$8.67M derived: sum of 3 quarters · filed 2025-03-04 | -$8.67M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | -$8.67M derived: sum of 2 quarters · filed 2025-03-04 | -$8.67M derived: sum of 3 quarters · filed 2025-03-04 | -$4.47M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$8.67M derived: sum of 2 quarters · filed 2025-03-04 | -$4.47M derived: sum of 3 quarters · filed 2025-03-04 | $0.00 10-K · filed 2025-03-04 | $8.67M 10-K · filed 2024-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.20M derived: sum of 2 quarters · filed 2024-11-13 | $8.67M 10-Q · filed 2024-11-13 | $14.49M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $8.67M 10-Q · filed 2024-08-13 | $14.49M derived: sum of 3 quarters · filed 2024-08-13 | $28.95M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $4.47M 10-Q · filed 2024-05-10 | $10.29M derived: sum of 2 quarters · filed 2024-05-10 | $24.75M derived: sum of 3 quarters · filed 2024-05-10 | $74.81M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $20.28M derived: sum of 2 quarters · filed 2024-03-21 | $70.34M derived: sum of 3 quarters · filed 2024-03-21 | $70.34M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $14.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $64.51M derived: sum of 2 quarters · filed 2023-11-13 | $64.51M 10-Q · filed 2023-11-13 | $64.51M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $50.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $50.06M 10-Q · filed 2023-08-14 | $50.06M derived: sum of 3 quarters · filed 2023-08-14 | $50.06M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |